Mayo Clinic proceedings
-
Mayo Clinic proceedings · Feb 2022
Social Determinants of Health Among Non-Elderly Adults With Stroke in the United States.
To examine the association of social determinants of health (SDOH) on prevalence of stroke in non-elderly adults (<65 years of age). ⋯ Nearly half of all non-elderly individuals with stroke have an unfavorable SDOH profile. Standardized assessment of SDOH risk burden may inform targeted strategies to mitigate disparities in stroke burden and outcomes in this population.
-
Mayo Clinic proceedings · Feb 2022
Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy.
To investigate a potential association between beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). ⋯ In this real-world, prospective, multi-institutional registry, patients with ATTR-CM who received beta blockers had lower all-cause mortality than untreated controls.
-
Mayo Clinic proceedings · Feb 2022
Retraction Of Publication Meta AnalysisTEMPORARY REMOVAL: Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
To maintain living, interactive evidence (LIvE) on the benefits and harms of different treatment options in adults with cancer-associated thrombosis (CAT). ⋯ Open Science Framework (https://osf.io/dth86).
-
Mayo Clinic proceedings · Feb 2022
Updated Reference Standards for Cardiorespiratory Fitness Measured with Cardiopulmonary Exercise Testing: Data from the Fitness Registry and the Importance of Exercise National Database (FRIEND).
To provide updated reference standards for cardiorespiratory fitness (CRF) for the United States derived from cardiopulmonary exercise (CPX) testing when using a treadmill or cycle ergometer. ⋯ These updated cardiorespiratory fitness reference standards improve the representativeness of the US population compared with the original standards.
-
Mayo Clinic proceedings · Feb 2022
Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases.
To verify the analytical performance of a new mass spectrometry-based method, termed MASS-FIX, when screening for plasma cell disorders in a routine clinical laboratory. ⋯ Overall, MASS-FIX was successful in maintaining validation characteristics. MASS-FIX was more sensitive in confirming SPEP abnormalities when compared with IFE. Ability to detect therapeutic monoclonal antibodies and glycosylated light chains was distinctly advantageous.